The predictive value of HER2 in breast cancer

Oncology

Volumn 61, Issue SUPPL. 2, 2001, Pages 73-82

  Piccart, Martine ^a   Lohrisch, Caroline ^a   Di Leo, Angelo ^a   Larsimont, Denis ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant therapy; Algorithm; Breast cancer; Chemotherapy; CMF; Endocrine therapy; HER2; Herceptin ; Predictive

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DROLOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; METHOTREXATE; PACLITAXEL; RECEPTOR SUBTYPE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; GENE AMPLIFICATION; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0034761909     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055405     Document Type: Conference Paper

References (59)

1. Overexpression of HER-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer
2. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
3. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first-line hormonal therapy
4. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology
5. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
6. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
7. HER2 overexpression predicts adjuvant tamoxifen (TAM) failure for early breast cancer (EBC): Complete data at 20 yr of the Naples GUN randomized trial
8. HER2/neu amplification predicts poor survival in node positive patients
9. First MAb approved for the treatment of metastatic breast cancer
10. Breast cancer trends of black women compared with white women
11. P53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
12. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing meta-static breast cancer that has progressed after chemotherapy for metastatic disease
13. A metanalysis of the interaction between Her2 and the response to endocrine therapy (ET) in metastatic breast cancer (MBC)
14. CMF or anthracycline-based adjuvant chemotherapy for node-positive (N+) breast cancer (BC) patients (PTS): 4 Year results of a Belgian randomised clinical trial with predictive markers analysis
15. Assessment of HER2 status in breast cancer: Why, when and how?
16. Prognostic factors in breast cancer
17. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
18. c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples
19. Prognostic factors in breast cancer
20. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer
21. Prognostic importance of c-erbB-2 expression in breast cancer
22. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2
23. Testing for HER2 status
24. A tumor marker utility grading system (TMUGS): A framework to evaluate clinical utility of tumor markers
25. Assessing the clinical impact of prognostic factors: When is 'statistically significant' clinically useful?
26. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors
27. Developments in chemotherapy of breast cancer
28. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
29. The biology of erbB-2/neu/HER-2 and its role in cancer
30. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy
31. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
32. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
33. Role of Herceptin® in primary breast cancer: Views from North America and Europe
34. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
35. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials
36. Breast cancer prognostic factors: Evaluation guidelines
37. Benefit of CMF treatment in lymph node-positive breast cancer overexpressing HER2
38. Effect of c-erbB(2) and estrogen receptor status on survival in women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil
39. Prolonged follow-up of the Swedish randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer and relationships to hormone receptor and ERBB2 levels
40. Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
41. Erb-B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor-negative breast cancer
42. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
43. Relationship between erbB-2 status and neoadjuvant chemotherapy response is dependent on anthracycline dose intensity
44. Integration of new therapies into management of metastatic breast cancer: A focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development
45. HER2: A 'predictive factor' ready to use in the daily management of breast cancer patients?
46. Initial report of the SWOG biological correlative study of C-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen (T) alone
47. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
48. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
49. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
50. Addition of HerceptinTM (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing meta-static breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
51. c-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
52. Erb-B2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer
53. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in Stage II breast cancer
54. First-line, non-hormonal, treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
55. The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples
56. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
57. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein